ConductScience.org, home

Paper39360565

Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.

Sharma P and 3 others. CPT Pharmacometrics Syst Pharmacol, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab. Papers, record 39360565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39360565

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.
PubMed
Journal
CPT Pharmacometrics Syst Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.82, provisional
iCite
Revised in PubMed
2026-07-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sharma PPradeephttps://orcid.org/0000-0003-3415-8917
2Boulton DWDavid Whttps://orcid.org/0000-0002-0668-7304
3Bertagnolli LNLynn Nhttps://orcid.org/0000-0002-3992-5620
4Tang WWeifenghttps://orcid.org/0000-0002-8261-8116

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Receptor, Interferon alpha-betaMajor topic
Models, BiologicalMajor topic
TranscriptomeMajor topic
Humans
Tissue Distribution
Lupus Erythematosus, Systemic
Antibodies, Monoclonal

Source PubMed

Download CSV of topics

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129644082Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.Lupus Sci Med2018https://conductscience.org/library/papers/29644082PubMed
225613900Proteomics. Tissue-based map of the human proteome.Science2015https://conductscience.org/library/papers/25613900PubMed
325601866Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.Front Immunol2014https://conductscience.org/library/papers/25601866PubMed
438229377Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol2019https://conductscience.org/library/papers/38229377PubMed
519199378The Simcyp population-based ADME simulator.Expert Opin Drug Metab Toxicol2009https://conductscience.org/library/papers/19199378PubMed
633629110Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.Rheumatology (Oxford)2021https://conductscience.org/library/papers/33629110PubMed
728956281Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus.Patient2018https://conductscience.org/library/papers/28956281PubMed
827909650PBPK modeling and simulation in drug research and development.Acta Pharm Sin B2016https://conductscience.org/library/papers/27909650PubMed
928392453Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.J Pharm Sci2017https://conductscience.org/library/papers/28392453PubMed
1028130918Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.Arthritis Rheumatol2017https://conductscience.org/library/papers/28130918PubMed
1135352835Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.J Clin Pharmacol2022https://conductscience.org/library/papers/35352835PubMed
1232141953Treatment of cutaneous lupus erythematosus: current approaches and future strategies.Curr Opin Rheumatol2020https://conductscience.org/library/papers/32141953PubMed
1322550964Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.Clin Pharmacokinet2012https://conductscience.org/library/papers/22550964PubMed
1436063748Correlation between IFNAR1 expression in peripheral blood T lymphocytes and inflammatory cytokines, tumor-infiltrating lymphocytes, and chemosensitivity in patients with colorectal cancer.Cytokine2022https://conductscience.org/library/papers/36063748PubMed
1521881594Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis.Genes Immun2012https://conductscience.org/library/papers/21881594PubMed
1614669296Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma.Cancer2003https://conductscience.org/library/papers/14669296PubMed
1725265476Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.PLoS One2014https://conductscience.org/library/papers/25265476PubMed
1829644080Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.Lupus Sci Med2018https://conductscience.org/library/papers/29644080PubMed
1926408308A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins.AAPS J2016https://conductscience.org/library/papers/26408308PubMed
2031236450Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE.J Patient Exp2019https://conductscience.org/library/papers/31236450PubMed

See all 43 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42382290Integrating in vitro aerosol characterization and cross-species PBPK modeling to predict human lung exposure of inhaled therapeutic proteins.Int J Pharm X2026https://conductscience.org/library/papers/42382290PubMed
42292405The landscape of cellular immune alteration in systemic lupus erythematosus.Front Immunol2026https://conductscience.org/library/papers/42292405PubMed
41459511Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases.Front Immunol2025https://conductscience.org/library/papers/41459511PubMed
39771538The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics2024https://conductscience.org/library/papers/39771538PubMed
39360565Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.CPT Pharmacometrics Syst Pharmacol2025https://conductscience.org/library/papers/39360565PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNAR13454PubTator's text mininghttps://conductscience.org/library/genes/3454

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39360565

GET https://conductscience.org/api/papers/v1/39360565/references?page=2